biotech
-
Obesity Drugs Are Becoming A Format And Margin Trade
Lilly’s Europe launch plan for an oral obesity pill, Novo Nordisk’s next-wave data, Chugai’s licensed discovery, and Hanmi’s muscle-preserving pipeline all suggest the GLP-1 trade is moving beyond a simple two-stock growth narrative.
-
Drug Stocks Are Starting To Trade Their Factory Maps, Not Just Their Pipelines
A fresh U.S. tariff clock, Roche’s June 4 backlash, Takeda’s global manufacturing footprint and Samsung Biologics’ new Maryland site all point to the same message: in pharma, location is becoming a market variable again.